Phenotypes associated with this allele

• Allele Symbol: P2ry2^tm1Bhk
• Allele Name: targeted mutation 1, Beverly Koller
• Allele ID: MGI:3613160
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	P2ry2^tm1Bhk/P2ry2^tm1Bhk	involves: 129P2/OlaHsd	MGI:3614645
hm2	P2ry2^tm1Bhk/P2ry2^tm1Bhk	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:3614643

Genotype
MGI:3614645

hm1

• Allelic Composition: P2ry2^tm1Bhk/P2ry2^tm1Bhk
• Genetic Background: involves: 129P2/OlaHsd

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

abnormal response/metabolism to endogenous compounds ( J:104694 )

• treatment with ATPgammaS in the presence of nerve growth factor does not increase dorsal root ganglion neuronal differentiation as in wild-type

• injection of ATPgammaS into the sciatic nerve does not increase growth-associated protein-43, a marker for axonal growth, as in wild-type

nervous system

abnormal neuron differentiation ( J:104694 )

• treatment with ATPgammaS in the presence of nerve growth factor does not increase dorsal root ganglion neuronal differentiation as in wild-type

abnormal axon extension ( J:104694 )

• injection of ATPgammaS into the sciatic nerve does not increase growth-associated protein-43, a marker for axonal growth, as in wild-type

cellular

abnormal neuron differentiation ( J:104694 )

• treatment with ATPgammaS in the presence of nerve growth factor does not increase dorsal root ganglion neuronal differentiation as in wild-type

abnormal axon extension ( J:104694 )

• injection of ATPgammaS into the sciatic nerve does not increase growth-associated protein-43, a marker for axonal growth, as in wild-type

Genotype
MGI:3614643

hm2

• Allelic Composition: P2ry2^tm1Bhk/P2ry2^tm1Bhk
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

homeostasis/metabolism

abnormal ion homeostasis ( J:57617 , J:57618 )

• intracellular calcium responses to nucleotides (UTP, ATP, ADP, UDP) are abolished in cultured lung fibroblasts (J:57617)

• intracellular calcium responses to UTP are abolished in tracheal and nasal epithelial cells and responses to ATP are substantially reduced in tracheal (74.5%) and nasal (44%) epithelial cells, however no reduction in calcium responses to ADP, 2-MeSATP, 2-MeSADP or UDP (J:57617)

• chloride secretory responses to UTP and ATP are reduced by 83-95% in excised tracheas and responses to alpha,beta-meATP (91%), 2-MeSATP (84%), and 2-MeSADP (54%) are substantially reduced, however no reduction in chloride secretory responses to UDP (J:57618)

• chloride secretory responses to ATP are reduced by 88% in excised gallbladders and responses to UTP are reduced by 30% in excised gallbladders, however no reduction in chloride secretory responses to UDP (J:57618)

• chloride secretory responses to nucleotides in the jejunum are not altered (J:57618)

abnormal response/metabolism to endogenous compounds ( J:57617 , J:57618 )

• intracellular calcium and inositol phosphate responses to nucleotides (UTP, ATP, ADP, UDP) are abolished in cultured lung fibroblasts (J:57617)

• intracellular calcium responses to UTP are abolished in tracheal and nasal epithelial cells and responses to ATP are substantially reduced in tracheal (74.5%) and nasal (44%) epithelial cells, however no reduction in calcium responses to ADP, 2-MeSATP, 2-MeSADP or UDP (J:57617)

• chloride secretory responses to UTP and ATP are reduced by 83-95% in excised tracheas and responses to alpha,beta-meATP (91%), 2-MeSATP (84%), and 2-MeSADP (54%) are substantially reduced, however no reduction in chloride secretory responses to UDP (J:57618)

• chloride secretory responses to ATP are reduced by 88% in excised gallbladders and responses to UTP are reduced by 30% in excised gallbladders, however no reduction in chloride secretory responses to UDP (J:57618)

• chloride secretory responses to nucleotides in the jejunum are not altered (J:57618)